GSK booth at ASCO 2026
Biotech

At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms

GSK shared early data suggesting its KIT inhibitor from IDRx could overtake Gleevec as the standard of care for gastrointestinal stromal tumors.
Darren Incorvaia Jun 1, 2026 3:55pm
Celcuity

ASCO: Why Celcuity dares to dream of becoming $10B company

Jun 2, 2026 8:01am
Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation
Telix booth at ASCO 2026

ASCO: Telix tees up pivotal test for Pluvicto challenger

Jun 1, 2026 4:12pm
Takeda

ASCO: Takeda touts ‘tremendous potential’ of Innovent bispecific

Jun 2, 2026 4:30am
ASCO

ASCO: BMS' bispecific ADC puts TROP2 drugs on notice

Jun 2, 2026 8:00am
More News

Roche oral SERD's 1st-line miss spurs new adjuvant trial

Jun 2, 2026 12:45pm

Travere scales Everest with $1.1B deal for BTK inhibitor

Jun 2, 2026 10:30am

ASCO: Cardiff posts updated colorectal data before pivotal push

Jun 2, 2026 9:06am

Fulcrum scraps SCD plan as FDA takes hard line on safety risks

Jun 2, 2026 8:46am